P&G beats earnings forecast; Alliance Pharma buys AZ anti-malarial brands;

 @FiercePharma: More on "how not to insider trade," with Bristol-Myers exec as exhibit A, from The Wall Street Journal. More | Follow @FiercePharma

> Procter & Gamble ($PG), which has attracted a large investment from William Ackman, beat earnings expectations. Story

> Alliance Pharma has ponied up £4.2 million ($6.5 million) for three anti-malarial brands from AstraZeneca ($AZN), Paludrine, Avloclor and Savarine, which it intends to sell mostly in Europe. Story  

> Biotech expert Eric Tomlinson is the new leader of North Carolina's Piedmont Triad Research Park. Story  

> Walgreen's fight with pharmacy benefits company Express Scripts cost it more sales than expected in July, partly accounting for a 7% slip. Story

> Ireland's Warner Chilcott ($WCRX) had lower revenue and earnings in its last quarter as slower U.S. sales and loss of a patent undercut its performance. Story

> China's ShangPharma has hired an adviser to evaluate a buyout offer from its CEO. Release

Medical Device News

@FierceMedDev: Globus scales back its IPO pricing, now trading under GMED. More | Follow @FierceMedDev

 @MarkHFierce: Thoratec reported a Q2 loss but is banking on continued sales growth to carry the year. More | Follow @MarkHFierce

 @DamianFierce: Study: U.S. access to new devices no slower than EU's. More | Follow @DamianFierce

> Study: U.S. access to new devices no slower than EU's. Report

> CA hospital accused of testing Stryker tech without patient consent. Article

> FDA whacks Philips unit with Class I ventilator recall. News

Biotech News

 @FierceBiotech: Yesterday's most popular story: Analyst reads last rites after heart failure scuttles Bristol hepatitis C study. Story | Follow @FierceBiotech

 @JohnCFierce: Bankers tally torrid pace for biotech M&A as hungry suitors pounce. More | Follow @JohnCFierce

 @RyanMFierce: A record for GSK? Asks for FDA approval for targeted melanoma treatment roughly 3 years after hitting the clinic. More | Follow @RyanMFierce

> J&J's boost in Doxil supply benefits study of Endocyte/Merck drug. Article

> Biotech startup Atterocor grabs $16M A round for cancer compound. More

> H1 venture deals: Celladon moves up in the rankings. Update

> Burrill & Co. boosts latest life sciences fund to $505M. News

> GSK races to regulators for approvals of new skin cancer drugs. Article

And Finally... The FDA has approved a drug with digestible sensors that can tell doctors if you have taken it. Story